We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · April 08, 2014

Aleglitazar Effect on CV Outcomes in Type 2 Diabetes

JAMA: The Journal of the American Medical Association


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA: The Journal of the American Medical Association
Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus: The AleCardio Randomized Clinical Trial
JAMA 2014 Mar 30;[EPub Ahead of Print], AM Lincoff, J-C Tardif, GG Schwartz, SJ Nicholls, L Rydén, B Neal, K Malmberg, HWedel, JB Buse, RR Henry, AWeichert, R Cannata, A Svensson, D Volz, DE Grobbee

Further Reading